Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) COO Eric Venker sold 100,000 shares of the stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $10.65, for a total transaction of $1,065,000.00. Following the completion of the transaction, the chief operating officer now owns 896,869 shares of the company's stock, valued at approximately $9,551,654.85. This represents a 10.03 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Eric Venker also recently made the following trade(s):
- On Thursday, February 13th, Eric Venker sold 218,041 shares of Roivant Sciences stock. The shares were sold at an average price of $10.42, for a total transaction of $2,271,987.22.
- On Tuesday, January 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.28, for a total transaction of $1,128,000.00.
- On Monday, December 30th, Eric Venker sold 177,704 shares of Roivant Sciences stock. The shares were sold at an average price of $11.54, for a total transaction of $2,050,704.16.
- On Friday, December 27th, Eric Venker sold 176,900 shares of Roivant Sciences stock. The shares were sold at an average price of $11.82, for a total transaction of $2,090,958.00.
- On Friday, December 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.49, for a total transaction of $1,149,000.00.
Roivant Sciences Stock Down 0.3 %
Shares of NASDAQ:ROIV opened at $10.49 on Wednesday. Roivant Sciences Ltd. has a 12 month low of $9.76 and a 12 month high of $13.06. The company's 50-day moving average price is $11.14 and its two-hundred day moving average price is $11.60. The firm has a market cap of $7.49 billion, a P/E ratio of -69.93 and a beta of 1.25.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last issued its quarterly earnings data on Monday, February 10th. The company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. As a group, equities analysts predict that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several research firms have recently weighed in on ROIV. HC Wainwright reaffirmed a "buy" rating and issued a $18.00 target price on shares of Roivant Sciences in a report on Tuesday, February 11th. Cantor Fitzgerald raised shares of Roivant Sciences to a "strong-buy" rating in a report on Thursday, January 30th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Buy" and an average price target of $18.08.
View Our Latest Stock Analysis on Roivant Sciences
Institutional Investors Weigh In On Roivant Sciences
A number of hedge funds have recently added to or reduced their stakes in ROIV. Norges Bank bought a new stake in Roivant Sciences during the 4th quarter worth about $52,443,000. TOMS Capital Investment Management LP bought a new position in shares of Roivant Sciences in the 3rd quarter valued at about $46,333,000. Invesco Ltd. boosted its stake in shares of Roivant Sciences by 49.7% in the 4th quarter. Invesco Ltd. now owns 9,515,058 shares of the company's stock valued at $112,563,000 after purchasing an additional 3,159,603 shares during the last quarter. FMR LLC boosted its stake in shares of Roivant Sciences by 5.6% in the 3rd quarter. FMR LLC now owns 49,145,056 shares of the company's stock valued at $567,134,000 after purchasing an additional 2,593,910 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of Roivant Sciences by 5.8% in the 4th quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company's stock valued at $521,553,000 after purchasing an additional 2,404,232 shares during the last quarter. Institutional investors own 64.76% of the company's stock.
Roivant Sciences Company Profile
(
Get Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
